SCHEMBL17465684

SCHEMBL17465684

CNCCNS(=O)(=O)c1ccc(F)c(C(=O)Nc2ccc(F)c(F)c2)c1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 12/20 0.60
MAPT P10636 11/20 0.60
RECQL P46063 1/20 0.60
POLB P06746 1/20 0.60
TP53 P04637 8/20 0.59
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
HTT P42858 3/20 0.57
KDM4E B2RXH2 2/20 0.56
MAPK1 P28482 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
ALDH1A1 P00352 2/20 0.54
GAA P10253 1/20 0.51
THRB P10828 1/20 0.51
CASP6 P55212 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL15847781 0.99 LMNA (0.59) LMNAMAPTRECQLPOLBTP53
SCHEMBL15613050 0.89 MAPT (0.61) LMNAMAPTRECQLPOLBTP53
SCHEMBL17465683 0.88 MAPT (0.60) LMNAMAPTRECQLPOLBTP53
SCHEMBL17668340 0.87 LMNA (0.59) LMNAMAPTRECQLPOLBTP53
Hydrochloric Acid SCHEMBL15847850 0.87 MAPT (0.59) LMNAMAPTRECQLPOLBTP53
SCHEMBL15847613 0.86 LMNA (0.58) LMNAMAPTRECQLPOLBTP53
SCHEMBL14488016 0.86 LMNA (0.58) LMNAMAPTRECQLPOLBTP53
SCHEMBL19332177 0.84 POLB (0.60) LMNAMAPTRECQLPOLBTP53
SCHEMBL17465676 0.83 LMNA (0.55) LMNAMAPTRECQLPOLBTP53
SCHEMBL14485055 0.83 MAPT (0.80) LMNAMAPTRECQLPOLBTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9938236-B2 Antiviral agents against HBV infection DREXEL UNIVERSITY (US) 2018-04-10 US disclosed
US-9938236-B2 Antiviral agents against HBV infection DREXEL UNIVERSITY (US) 2018-04-10 US disclosed
US-20160024004-A1 NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-01-28 US disclosed
US-20160024004-A1 NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024004-A1 NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION HAVCR2, EIF2AK2, NR1H4 LMNA 1478/4885MAPT 4494/4885RECQL 336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.